BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
2.850
+0.150 (5.56%)
At close: Mar 1, 2024, 4:00 PM
2.860
+0.010 (0.35%)
After-hours: Mar 1, 2024, 6:26 PM EST
5.56%
Market Cap 136.62M
Revenue (ttm) n/a
Net Income (ttm) -124.08M
Shares Out 47.80M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 546,530
Open 2.680
Previous Close 2.700
Day's Range 2.655 - 2.855
52-Week Range 1.240 - 4.068
Beta 0.82
Analysts Strong Buy
Price Target 13.67 (+379.65%)
Earnings Date Mar 21, 2024

About BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 66
Stock Exchange NASDAQ
Ticker Symbol BCAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for BCAB stock is "Strong Buy." The 12-month stock price forecast is $13.67, which is an increase of 379.65% from the latest price.

Price Target
$13.67
(379.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

2 months ago - GlobeNewsWire

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Multiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and i...

2 months ago - GlobeNewsWire

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints

3 months ago - GlobeNewsWire

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 months ago - GlobeNewsWire

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

4 months ago - GlobeNewsWire

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

4 months ago - GlobeNewsWire

BioAtla's Jay M. Short, Ph.D.

SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

5 months ago - GlobeNewsWire

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

5 months ago - GlobeNewsWire

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

6 months ago - GlobeNewsWire

BioAtla to Participate in Upcoming Investor Conferences in August

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

7 months ago - GlobeNewsWire

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

7 months ago - GlobeNewsWire

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

7 months ago - GlobeNewsWire

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

8 months ago - GlobeNewsWire

BioAtla to Participate in the Jefferies Healthcare Conference

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera...

9 months ago - GlobeNewsWire

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera...

10 months ago - GlobeNewsWire

BioAtla to Participate in the JMP Securities Life Sciences Conference

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera...

10 months ago - GlobeNewsWire

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera...

10 months ago - GlobeNewsWire

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23

1 year ago - GlobeNewsWire

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

1 year ago - GlobeNewsWire

BioAtla Announces Change in Executive Leadership

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

1 year ago - GlobeNewsWire

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

1 year ago - GlobeNewsWire

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Other symbols: AFMDEIGRIMRXNKTXTIL
1 year ago - Barrons

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

1 year ago - GlobeNewsWire